Coronavirus COVID-19 Outbreak – What's New
Updated: Wednesday, January 13, 2021 17:24 ET
COVID-19 Cases
Around the Globe
Recent Confirmed Cases in countries with the highest reported COVID-19 activity (India, United States, Brazil, France, Russia, UK, Turkey, Italy, Spain). Note that the left axis is linear rather than logarithmic and representsthe number of cases reported (rolling 7-day average) by each country.
Data sources: Johns Hopkins Center for Systems Science and Engineering (CSSE). Our World in Data.
- See Comparison of Epidemic Curves by Country for details.
In the United States
Key COVID-19 metrics in the United States since April 1, 2020. Dark lines represent 7-day averages.
Source: The COVID-19 Tracking Project[2]
US COVID-19 Case Rate Reported to the CDC in the Last 7 Days, by State/Territory (cases per 100K).
Source: US Centers for Disease Control and Prevention.
Aggregate data from the Centers for Disease Control and Prevention (CDC) and state- and local-level public health agencies. County-level data is confirmed by referencing state and local agencies directly. Map shows percent change in deaths from previous7 days as of January 3, 2020.
Source: US Centers for Disease Control
Cases | Deaths | |||||
State | Total | ⇓ Last 7d | Per 100k | Total | Last 7d | Per 100k |
California | 2,747,288 | 294,954 | 6,953 | 30,513 | 3,510 | 113 |
Texas | 1,995,292 | 152,139 | 6,881 | 30,219 | 2,000 | 136 |
Florida | 1,476,484 | 108,706 | 6,874 | 23,227 | 1,039 | 0 |
New York | 665,919 | 73,401 | 6,024 | 14,050 | 887 | 144 |
Arizona | 636,100 | 68,626 | 8,739 | 10,482 | 1,165 | 77 |
Georgia | 773,692 | 67,538 | 7,287 | 11,662 | 590 | 91 |
North Carolina | 635,975 | 60,579 | 6,064 | 7,638 | 642 | 180 |
Pennsylvania | 733,429 | 59,514 | 5,729 | 18,080 | 1,534 | 116 |
Ohio | 792,938 | 57,935 | 6,784 | 9,802 | 555 | 101 |
New Jersey | 594,749 | 52,879 | 6,696 | 20,039 | 657 | 108 |
Illinois | 1,040,168 | 48,449 | 8,208 | 19,497 | 935 | 0 |
New York City | 506,377 | 43,709 | 6,029 | 25,742 | 379 | 109 |
Tennessee | 660,874 | 43,225 | 9,677 | 8,011 | 744 | 74 |
Massachusetts | 432,370 | 42,841 | 6,273 | 13,204 | 532 | 21 |
Indiana | 570,477 | 37,394 | 8,474 | 9,104 | 441 | 133 |
Virginia | 412,545 | 35,245 | 4,833 | 5,552 | 326 | 87 |
South Carolina | 359,357 | 31,284 | 6,980 | 5,860 | 362 | 153 |
Oklahoma | 346,621 | 29,076 | 8,760 | 2,858 | 216 | 135 |
Alabama | 407,848 | 28,255 | 8,318 | 5,573 | 687 | 111 |
Kentucky | 308,729 | 27,893 | 6,910 | 2,944 | 172 | 65 |
Louisiana | 352,939 | 26,291 | 7,592 | 7,971 | 336 | 171 |
Michigan | 570,150 | 23,508 | 5,709 | 14,296 | 688 | 191 |
Wisconsin | 555,249 | 23,359 | 9,536 | 5,633 | 267 | 105 |
Maryland | 314,867 | 21,963 | 5,208 | 6,404 | 272 | 33 |
Missouri | 427,117 | 21,528 | 6,959 | 6,155 | 330 | 143 |
Utah | 309,629 | 20,678 | 9,658 | 1,422 | 110 | 102 |
Arkansas | 259,553 | 20,665 | 8,601 | 4,121 | 285 | 100 |
Connecticut | 217,047 | 20,079 | 6,088 | 6,449 | 257 | 3 |
What’s New Elsewhere
Feedback
Share this page
References
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. [PMID:32087114]
- Nationwide COVID-19 Metrics Since April 1. The COVID Tracking Project. [https://covidtracking.com/data/charts/us-all-key-metrics]
- Abbasi J. The Promise and Peril of Antibody Testing for COVID-19. JAMA. 2020. [PMID:32301958]
- Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level. JAMA. 2020. [PMID:32412582]
- Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. [PMID:32471884]
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020. [PMID:32445440]
- Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020. [PMID:32412710]
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020. [PMID:32492293]
- Brooks JT, Butler JC, Redfield RR. Universal Masking to Prevent SARS-CoV-2 Transmission-The Time Is Now. JAMA. 2020. [PMID:32663243]
- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 27 June 2020.
- Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020. [PMID:32644129]
- Cavalcanti AB et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. July 23, 2020 DOI: 10.1056/NEJMoa2019014
- Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020. [PMID:32434946]
- Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020. [PMID:32219057]
- Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020. [PMID:32497510]
- Coronavirus Disease 2019 (COVID-19) Situation Reports. World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-...]
- Coronavirus Locations: COVID-19 Map by County and State. USAFacts.org. [https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/]
- Coronavirus in the U.S.: Latest Map and Case Count. New York Times. [https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html]
- Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020. [PMID:32598830]
- Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020. [PMID:32558485]
- Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020. [PMID:32598831]
- Gao Q, Bao L, Mao H, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020. [PMID:32376603]
- Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020. [PMID:32379955]
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020. [PMID:32459919]
- Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020. [PMID:32275812]
- Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020. [PMID:32402157]
- Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020. [PMID:32692365]
- Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020. [PMID:32401715]
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020. [PMID:32663912]
- Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020. [PMID:32391855]
- Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413. [PMID:32217705]
- Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020. [PMID:32492084]
- Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020. [PMID:32227757]
- Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422. [PMID:32546467]
- Mahase E. Covid-19: What is the evidence for cloth masks? BMJ. 2020;369:m1422. [PMID:32265341]
- Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. [PMID:32450107]
- Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020. [PMID:32303591]
- Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis. 2020. [PMID:32628269]
- NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [News]. US National Institute of Allergy and Infectious Diseases. April 29, 2020. [https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-...]
- NIH clinical trial of investigational vaccine for COVID-19 begins: study enrolling Seattle-based healthy adult volunteers [News]. March 16, 2020. [https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investiga...]
- Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020;395(10236):1525-1527. [PMID:32423580]
- Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101-1102. [PMID:32247384]
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020. [PMID:32645347]
- RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020. [PMID:32678530]
- Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. U.S. Centers for Disease Control and Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-...]
- Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020. [PMID:32392282]
- Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA. 2020. [PMID:32421155]
- Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020. [PMID:32374370]
- Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020. [PMID:32269068]
- Situation update worldwide. European Centre for Disease Prevention and Control. [https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases]
- Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020. [PMID:32673060]
- Stringhini S et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. June 11, 2020. S0140-6736(20)31304-0. [https://doi.org/10.1016/]
- Studdert DM, Hall MA. Disease Control, Civil Liberties, and Mass Testing - Calibrating Restrictions during the Covid-19 Pandemic. N Engl J Med. 2020. [PMID:32272003]
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. [PMID:32409561]
- Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263. [PMID:32513810]
- Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020. [PMID:32302379]
- Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. [PMID:32410760]
- Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020. [PMID:32532802]
- Wang X, Ferro EG, Zhou G, et al. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA. 2020. [PMID:32663246]
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. [PMID:32423584]
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020. [PMID:32648899]
- Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020. [PMID:32502334]
Coronavirus COVID-19 Outbreak – What's Newis the Relief Central Word of the day!